Transcranial magnetic stimulation in the treatment of substance addiction
Annals of the New York Academy of Sciences (Impact Factor: 4.38). 07/2014; 1327(1). DOI: 10.1111/nyas.12479
Transcranial magnetic stimulation (TMS) is a noninvasive method of brain stimulation used to treat a variety of neuropsychiatric disorders, but is still in the early stages of study as addiction treatment. We identified 19 human studies using repetitive TMS (rTMS) to manipulate drug craving or use, which exposed a total of 316 adults to active rTMS. Nine studies involved tobacco, six alcohol, three cocaine, and one methamphetamine. The majority of studies targeted high-frequency (5–20 Hz; expected to stimulate neuronal activity) rTMS pulses to the dorsolateral prefrontal cortex. Only five studies were controlled clinical trials: two of four nicotine trials found decreased cigarette smoking; the cocaine trial found decreased cocaine use. Many aspects of optimal treatment remain unknown, including rTMS parameters, duration of treatment, relationship to cue-induced craving, and concomitant treatment. The mechanisms of rTMS potential therapeutic action in treating addictions are poorly understood, but may involve increased dopamine and glutamate function in corticomesolimbic brain circuits and modulation of neural activity in brain circuits that mediate cognitive processes relevant to addiction, such as response inhibition, selective attention, and reactivity to drug-associated cues. rTMS treatment of addiction must be considered experimental at this time, but appears to have a promising future.
- [Show abstract] [Hide abstract]
ABSTRACT: Theoretically, harnessing the brain's own endogenous plasticity mechanisms could serve to alter both internal states and external behavior in a therapeutic manner.Neuron 09/2014; 83(6):1259-1261. DOI:10.1016/j.neuron.2014.08.022 · 15.05 Impact Factor
- Progress in brain research 01/2015; DOI:10.1016/bs.pbr.2015.07.009 · 2.83 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: The prevention and treatment of substance use disorders (SUD), including addiction would benefit from having better biomarkers for the classification of patients into categories that are reproducible and have predictive validity. Direct measurement of drugs or their metabolites in various body fluids constitutes a clinically valuable biomarker, but one that can only be used to corroborate acute, or relatively recent drug use. Thus, there is an urgent need for biomarkers that reflect chronic drug exposure as well as biomarkers that predict or correlate with disease trajectories and treatment responses. Advances in tools and technologies to investigate genetics, epigenetics and epitranscriptomics, and human brain function and neurochemistry (brain imaging tools including EEG) offer unprecedented opportunities for the development of such biomarkers. Progress in this area will not only enhance our ability to screen and treat patients with SUD but also accelerate research on the neurobiological processes that underlie SUD.ACS Chemical Neuroscience 03/2015; 6(4). DOI:10.1021/acschemneuro.5b00067 · 4.36 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.